Fulcrum Therapeutics, Inc.·4

Jan 21, 4:15 PM ET

Oltmans Curtis Gale 4

4 · Fulcrum Therapeutics, Inc. · Filed Jan 21, 2022

Insider Transaction Report

Form 4
Period: 2022-01-19
Oltmans Curtis Gale
Chief Legal Officer
Transactions
  • Award

    Stock Option (right to buy)

    2022-01-19+60,00060,000 total
    Exercise: $12.69Exp: 2032-01-18Common Stock (60,000 underlying)
Footnotes (1)
  • [F1]This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION